Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00788736 · ClinicalTrials.gov registry record
Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism
A clinical trial, sponsored by Ottawa Hospital Research Institute.
- Completed
- Registry status
- 2,537
- Enrollment target
NCT00788736: Completed study, sponsored by Ottawa Hospital Research Institute.
NCT00788736 is a clinical trial that has completed, run by Ottawa Hospital Research Institute. The registered enrollment target is 2,537 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00788736 has completed, sponsored by Ottawa Hospital Research Institute.
- COMPLETED
- Registry status
- 2,537 participants
- Enrollment target
Study Summary
The main objective of the study is to develop or validate a clinical prediction rule for major bleeding in patients on oral anticoagulant therapy who have been safely anticoagulated without bleeding or venous thromboembolism (VTE) recurrence for at least 3 months since diagnosis and are being considered for long-term oral anticoagulant therapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,537 participants |
| Start Date | 2008-09 |
| Est. Completion | 2016-10 |
What the finished NCT00788736 record still lists
NCT00788736 is an observational study that tracks outcomes without assigning an intervention. Its 2,537 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00788736 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00788736 about?
NCT00788736 is a clinical study titled "Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism". The main objective of the study is to develop or validate a clinical prediction rule for major bleeding in patients on oral anticoagulant therapy who have been safely anticoagulated without bleeding or venous thromboembolism (VTE) recurrence for at least 3 months since diagnosis and are being consid...
What is the current status of trial NCT00788736?
This trial is currently completed. The enrollment target is 2,537 participants. The study started on 2008-09. Estimated completion is 2016-10.
Who is sponsoring clinical trial NCT00788736?
This trial is sponsored by Ottawa Hospital Research Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05931276 · 2,540 participants · Phase 3
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
- NCT00018057 · 2,530 participants · Phase 2
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
- NCT04142177 · 2,529 participants · NA
Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response
- NCT06018285 · 2,572 participants · NA
Stepped Approach to Reducing Risk of Suicide in Primary Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia